NCT00075400 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 23
- units
- Participants
- groups
- description
- Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.
- id
- BG000
- title
- Gleevec
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.2
- value
- 64.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- 40-49 years
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- 50-59 years
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- 60-69 years
- categories
- measurements
- group Id
- BG000
- value
- 4
- title
- 70-79 years
- categories
- measurements
- group Id
- BG000
- value
- 2
- title
- 80-89 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- param Type
- NUMBER
- title
- FIGO (International Federation of Gynecology and Obstetrics) Stage Recurrent/Persistent
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Carcinosarcoma-homologous
- categories
- measurements
- group Id
- BG000
- value
- 8
- title
- Carcinosarcoma-heterologous
- categories
- measurements
- group Id
- BG000
- value
- 12
- title
- Carcinosarcoma, Malignant Mixed Mullerian Tumor
- param Type
- NUMBER
- title
- Histologic Type
- unit Of Measure
- participants
- population Description
- Eligible and treated patients.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 23
- units
- Participants
- groups
- description
- Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.
- id
- BG000
- title
- Gleevec
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.2
- value
- 64.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- 40-49 years
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- 50-59 years
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- 60-69 years
- categories
- measurements
- group Id
- BG000
- value
- 4
- title
- 70-79 years
- categories
- measurements
- group Id
- BG000
- value
- 2
- title
- 80-89 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 23
- param Type
- NUMBER
- title
- FIGO (International Federation of Gynecology and Obstetrics) Stage Recurrent/Persistent
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Carcinosarcoma-homologous
- categories
- measurements
- group Id
- BG000
- value
- 8
- title
- Carcinosarcoma-heterologous
- categories
- measurements
- group Id
- BG000
- value
- 12
- title
- Carcinosarcoma, Malignant Mixed Mullerian Tumor
- param Type
- NUMBER
- title
- Histologic Type
- unit Of Measure
- participants
- population Description
- Eligible and treated patients.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle